» Articles » PMID: 27981684

Gastrointestinal Symptom Severity in Irritable Bowel Syndrome, Inflammatory Bowel Disease and the General Population

Overview
Date 2016 Dec 17
PMID 27981684
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) patients report similar gastrointestinal (GI) symptoms, yet comparisons of symptom severity between groups and with the general population (GP) are lacking.

Methods: We compared Patient-Reported Outcomes Measurement Information System (PROMIS ) GI symptom scales measuring gastro-esophageal reflux (GER), disrupted swallowing, diarrhea, bowel incontinence, nausea/vomiting, constipation, belly pain, and gas/bloating in: (i) USA GP sample, (ii) IBS patients, and (iii) IBD patients from tertiary care and community populations. Symptom severity scores were based on T-score metric with mean 50±10 (standard deviation) relative to the GP.

Key Results: Of 1643 patients enrolled, there were 253 IBS patients (68% F, mean age 45±15 years), 213 IBD patients (46% F, mean age 41±14 years), and 1177 GP subjects (57% F, mean age 46±16 years). IBS patients reported greater severity of GER, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating, and constipation symptoms than their IBD counterparts (all P<.05). Compared to the GP, IBD patients had worse belly pain, gas/bloating, diarrhea, and bowel incontinence, but less severe GER and disrupted swallowing (all P<.05), and IBS patients had more severe nausea/vomiting, belly pain, gas/bloating, and constipation (all P<.05). Women had more severe belly pain and gas/bloating than men, whereas men had more severe bowel incontinence (all P<.05).

Conclusion & Inferences: IBS and IBD are associated with more severe GI symptoms compared to the GP excluding esophageal symptoms. Unlike IBD, IBS is not characterized by observable GI inflammation but patients report more severe upper and lower GI symptoms.

Citing Articles

Mirtazapine for gastrointestinal and neuropsychological symptoms in older adults with irritable bowel syndrome.

Khan A, Menon R, Corning B, Cohn S, Kumfa C, Raji M Therap Adv Gastroenterol. 2024; 18:17562848241278125.

PMID: 39493642 PMC: 11526313. DOI: 10.1177/17562848241278125.


Effects of proton pump inhibitors on inflammatory bowel disease: An updated review.

Liang Y, Meng Z, Ding X, Jiang M World J Gastroenterol. 2024; 30(21):2751-2762.

PMID: 38899331 PMC: 11185295. DOI: 10.3748/wjg.v30.i21.2751.


Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives.

Abouelela M, Helmy Y Microorganisms. 2024; 12(3).

PMID: 38543481 PMC: 10972033. DOI: 10.3390/microorganisms12030430.


Functional somatic syndromes are associated with inferior outcomes and increased complications after hip and knee arthroplasty: a systematic review.

Masood R, Mandalia K, Pagani N, Moverman M, Puzzitiello R, Menendez M Arthroplasty. 2024; 6(1):2.

PMID: 38173047 PMC: 10765755. DOI: 10.1186/s42836-023-00223-1.


Aging is Associated With Constipation in Japanese Patients With Ulcerative Colitis: A Post Hoc Analysis.

Yagi S, Furukawa S, Miyake T, Yoshida O, Shiraishi K, Tange K Gerontol Geriatr Med. 2023; 9:23337214231215637.

PMID: 38035264 PMC: 10683382. DOI: 10.1177/23337214231215637.


References
1.
Naliboff B, Munakata J, Fullerton S, Gracely R, Kodner A, Harraf F . Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut. 1997; 41(4):505-12. PMC: 1891510. DOI: 10.1136/gut.41.4.505. View

2.
Sydora M, Sydora B, Fedorak R . Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012; 6(2):207-14. DOI: 10.1016/j.crohns.2011.08.008. View

3.
Pierret J . The illness experience: state of knowledge and perspectives for research. Sociol Health Illn. 2003; 25:4-22. DOI: 10.1111/1467-9566.t01-1-00337. View

4.
Lovell R, Ford A . Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012; 107(7):991-1000. DOI: 10.1038/ajg.2012.131. View

5.
Khanna D, Krishnan E, Morgan DeWitt E, Khanna P, Spiegel B, Hays R . The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S486-90. PMC: 3302685. DOI: 10.1002/acr.20581. View